eMedicine Specialties > Dermatology > Metabolic Diseases

Amyloidosis, Nodular Localized Cutaneous: Differential Diagnoses & Workup

Author: Marion C Miethke, MD, Clinical Assistant Professor, Department of Internal Medicine, Section of Dermatology, University of Washington
Coauthor(s): Gregory J Raugi, MD, PhD, Professor, Department of Internal Medicine, Division of Dermatology, University of Washington at Seattle; Chief, Dermatology Section, Primary and Specialty Care Service, Veterans Administration Medical Center of Seattle
Contributor Information and Disclosures

Updated: Jan 23, 2007

Differential Diagnoses

Colloid Milium
Leiomyoma
Pretibial Myxedema
Pseudolymphoma, Cutaneous

Workup

Laboratory Studies

  • Normal serum protein electrophoresis and urine protein electrophoresis studies exclude multiple myeloma.
  • Positive antinuclear, anti-Ro, and anti-La antibodies indicate Sjögren syndrome.
  • Laboratory studies, such as CBC, serum chemistry profile, and liver function tests often were part of a general workup in several case reports of patients with NLCA. NLCA does not cause any abnormal findings in these studies.
  • Urinalysis or 24-hour urine testing can be performed to check for protein. Proteinuria is not a feature of localized cutaneous disease but can be seen in systemic amyloidosis.

Imaging Studies

  • In some patients, imaging studies have included chest radiography, ECG, and abdominal ultrasonography.
  • Screening for amyloid within organs can be accomplished using scintigraphy with radioiodinated serum amyloid P component (ie, SAP scanning).

Procedures

  • Skin biopsy provides the definitive diagnosis. No special tissue preparation or handling is required before delivering the specimen to the laboratory. Special stains and immunohistochemistry are helpful.
  • Sites for an optimal biopsy include the epidermis, papillary dermis, and reticular dermis. The amyloid in NLCA is located in the reticular dermis and clearly differentiates NLCA from other forms of amyloidosis. A shave biopsy or other superficial sample may not include enough reticular dermis to complete the diagnosis.
  • Consider bone marrow biopsy with gene rearrangement studies (if available) to exclude multiple myeloma.

Histologic Findings

Despite their biochemical heterogeneity, all "amyloid" deposits demonstrate a similar light microscopic appearance. They are eosinophilic and homogeneous when stained with hematoxylin and eosin and viewed with standard optics. When stained with Congo red and viewed with polarized light, deposits exhibit a characteristic and diagnostic green birefringence. Clinical morphology reflects underlying histology. Amyloid is not limited to the papillary dermis but is present in the entire dermis and in subcutaneous fat (unlike lichenoid or macular types) and may be seen within the walls of small blood vessels (see Media Files 1-3).

Plasma cells, which most likely produce the amyloid, occur within an adjacent and intermingled inflammatory infiltrate. They can be sparse or numerous (similar plasma cell infiltrate occurs in nodular pulmonary amyloidosis but usually is absent in cutaneous lesions of primary systemic amyloidosis). When eosinophilic amyloid material is exposed to potassium permanganate prior to staining with Congo red, the amyloid retains its congophilia, similar to systemic amyloidosis but in contradistinction to secondary amyloidosis.

When viewed with a transmission electron microscope, the apparently homogeneous deposits of amyloid are composed of loosely interwoven 6- to 10-nm–thick straight filaments. The amino acids of the filament proteins are arranged in a characteristic beta-pleated sheet tertiary structure. Amyloid deposits in the skin also contain small amounts of a plasma-derived, nonfibrillar, amyloid-P protein.

More on Amyloidosis, Nodular Localized Cutaneous

Overview: Amyloidosis, Nodular Localized Cutaneous
Differential Diagnoses & Workup: Amyloidosis, Nodular Localized Cutaneous
Treatment & Medication: Amyloidosis, Nodular Localized Cutaneous
Follow-up: Amyloidosis, Nodular Localized Cutaneous
Multimedia: Amyloidosis, Nodular Localized Cutaneous
References
[ CLOSE WINDOW ]

References

  1. Alster TS, Manaloto RM. Nodular amyloidosis treated with a pulsed dye laser. Dermatol Surg. Feb 1999;25(2):133-5. [Medline].

  2. Bozikov K, Janezic T. Excision and split thickness skin grafting in the treatment of nodular primary localized cutaneous amyloidosis. Eur J Dermatol. May-Jun 2006;16(3):315-6. [Medline].

  3. Breathnach SM. Amyloid and amyloidosis. J Am Acad Dermatol. Jan 1988;18(1 Pt 1):1-16. [Medline].

  4. Carroll CB, Collison DW, Rodman OG Jr. Atrophic outpouchings of abdominal skin. Nodular cutaneous amyloidosis. Arch Dermatol. Feb 1996;132(2):223-4, 226-7. [Medline].

  5. Grunewald K, Sepp N, Weyrer K, et al. Gene rearrangement studies in the diagnosis of primary systemic and nodular primary localized cutaneous amyloidosis. J Invest Dermatol. Oct 1991;97(4):693-6. [Medline].

  6. Hagari Y, Mihara M, Hagari S. Nodular localized cutaneous amyloidosis: detection of monoclonality of infiltrating plasma cells by polymerase chain reaction. Br J Dermatol. Oct 1996;135(4):630-3. [Medline].

  7. Hamzavi I, Lui H. Excess tissue friability during CO2 laser vaporization of nodular amyloidosis. Dermatol Surg. Sep 1999;25(9):726-8. [Medline].

  8. Helm TN, Danziger J, Helm KF. Bilateral plantar amyloidosis: a unique presentation of localized cutaneous amyloidosis. Cutis. Mar 1997;59(3):142-4. [Medline].

  9. Hicks BC, Weber PJ, Hashimoto K, et al. Primary cutaneous amyloidosis of the auricular concha. J Am Acad Dermatol. Jan 1988;18(1 Pt 1):19-25. [Medline].

  10. Horiguchi Y, Takahashi C, Imamura S. A case of nodular cutaneous amyloidosis. Amyloid production by infiltrating plasma cells. Am J Dermatopathol. Feb 1993;15(1):59-63. [Medline].

  11. Huilgol SC, Ramnarain N, Carrington P,et al. Cytokeratins in primary cutaneous amyloidosis. Australas J Dermatol. May 1998;39(2):81-5. [Medline].

  12. Inazumi T, Hakuno M, Yamada H, et al. Characterization of the amyloid fibril from primary localized cutaneous nodular amyloidosis associated with Sjogren''s syndrome. Dermatology. 1994;189(2):125-8. [Medline].

  13. Lien MH, Railan D, Nelson BR. The efficacy of dermabrasion in the treatment of nodular amyloidosis. J Am Acad Dermatol. Feb 1997;36(2 Pt 2):315-6. [Medline].

  14. Masuda C, Hayashi M, Kameda Y, et al. Protein AL origin in amyloidosis cutis nodularis atrophicans. J Dermatol. Aug 1986;13(4):280-4. [Medline].

  15. Masuda C, Mohri S, Nakajima H. Histopathological and immunohistochemical study of amyloidosis cutis nodularis atrophicans--comparison with systemic amyloidosis. Br J Dermatol. Jul 1988;119(1):33-43. [Medline].

  16. Mun KS, Pailoor J, Reddy SC. Primary localised deep cutaneous amyloidosis of the eyelid. Malays J Pathol. Dec 2005;27(2):113-5. [Medline].

  17. Northcutt AD, Vanover MJ. Nodular cutaneous amyloidosis involving the vulva. Case report and literature review. Arch Dermatol. Apr 1985;121(4):518-21. [Medline].

  18. Srivastava M. Primary cutaneous nodular amyloidosis in a patient with Sjogren's syndrome. J Drugs Dermatol. Mar 2006;5(3):279-80. [Medline].

  19. Touart DM, Sau P. Cutaneous deposition diseases. Part I. J Am Acad Dermatol. Aug 1998;39(2 Pt 1):149-71; quiz 172-4. [Medline].

  20. Trau H, Shpiro D, Schewach-Millet M, et al. Nodular cutaneous amyloidosis. Am J Dermatopathol. Aug 1991;13(4):414-7. [Medline].

  21. Truhan AP, Garden JM, Roenigk HH Jr. Nodular primary localized cutaneous amyloidosis: immunohistochemical evaluation and treatment with the carbon dioxide laser. J Am Acad Dermatol. Jun 1986;14(6):1058-62. [Medline].

  22. Vestey JP, Tidman MJ, Mclaren KM. Primary nodular cutaneous amyloidosis--long-term follow-up and treatment. Clin Exp Dermatol. Mar 1994;19(2):159-62. [Medline].

  23. Yoneyama K, Tochigi N, Oikawa A, et al. Primary localized cutaneous nodular amyloidosis in a patient with Sjogren's syndrome: a review of the literature. J Dermatol. Feb 2005;32(2):120-3. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

amyloidosis cutis nodularis atrophicans, nodular localized cutaneous amyloidosis

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Marion C Miethke, MD, Clinical Assistant Professor, Department of Internal Medicine, Section of Dermatology, University of Washington
Marion C Miethke, MD is a member of the following medical societies: Phi Beta Kappa
Disclosure: Nothing to disclose.

Coauthor(s)

Gregory J Raugi, MD, PhD, Professor, Department of Internal Medicine, Division of Dermatology, University of Washington at Seattle; Chief, Dermatology Section, Primary and Specialty Care Service, Veterans Administration Medical Center of Seattle
Gregory J Raugi, MD, PhD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

Medical Editor

C Lisa Kauffman, MD, FACP, Professor, Chief, Division of Dermatology, Departments of Medicine and Pathology, Georgetown University Medical Center
C Lisa Kauffman, MD, FACP is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Royal Society of Medicine, Society for Investigative Dermatology, and Women's Dermatologic Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Warren R Heymann, MD, Head, Division of Dermatology, Professor, Department of Internal Medicine, University of Medicine and Dentistry of New Jersey
Warren R Heymann, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

CME Editor

Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.